19
DYNAMICS OF SUCCESS Desitin Company Profile
DYNAMICS OF SUCCESSDesitin Company Profile
Founded 100 years ago in Hamburg Independent, family-owned, profitable company,
based in Hamburg About 300 employees in development, production,
sales, medicine, marketing and administration Established as a specialist in the fields of epilepsy
and Parkinson’s disease Addition of further CNS indications General managers
Philipp Bloching MD, Martin Schütt and Christoph Steinschulte PhD
Our Heritage: Medium-sized, SpecializedPharmaceutical Company
15.11.2020DYNAMICS OF SUCCESS I Desitin Company Profile2
Desitin Arzneimittel GmbH Weg beim Jaeger 214
22335 Hamburg Germany
Phone: +49 40 59101-0 Email: [email protected]
Our Headquarters and Place of Production
15.11.2020DYNAMICS OF SUCCESS I Desitin Company Profile3
Our Strategy
15.11.2020DYNAMICS OF SUCCESS I Desitin Company Profile4
Rx productsConcentration on special
in European countries with
successful partnerships, licensing agreements
and own R&D
In-depth knowledge in epilepsy and Parkinson's disease High medical expertise knowledge in dystonia,
psychiatry, addiction, sleeping disorders Success stories in scientific marketing of own and
in-licensed Rx-products Close networking with key opinion leaders Relationships to patient organizations in
several indications
Our Expertise: CNS Indications
15.11.2020DYNAMICS OF SUCCESS I Desitin Company Profile5
Product and target-group specific sales strategies Subsidiaries with sales teams in 11 European countries Distribution partners in further 15 European countries
Our Expertise: Pan-European Distribution Network
15.11.2020DYNAMICS OF SUCCESS I Desitin Company Profile6
15.11.2020DYNAMICS OF SUCCESS I Desitin Company Profile7
DESITIN - A EUROPEAN CNS FORCE
Our Commercial Structure
KEY COUNTRIES(WITH OWN AFFILIATES)
Germany, Norway, Denmark, Sweden,Switzerland, Czech Republic, Slovakia,Romania, U. K., Estonia, Moldova
PARTNER COUNTRIES(WITH LOCAL DISTRIBUTORS)
Austria, Belgium, Croatia, Finland,France, Hungary, Iceland, Netherlands,Portugal, Spain, Turkey
8
Current Main Partner in Pan-EU Network
15.11.2020DYNAMICS OF SUCCESS I Desitin Company Profile
France Spain Portugal Netherlands Belgium Finland Austria Croatia Hungary Iceland
Long experience in development ofproducts with different application forms In-house production of pharmaceutical
products Strong regulatory know-how for
European markets
Our Expertise: Fully-Integrated Pharmaceutical Company
15.11.2020DYNAMICS OF SUCCESS I Desitin Company Profile9
Driving Growth by Own Developments
15.11.2020DYNAMICS OF SUCCESS I Desitin Company Profile10
1982Rectal tubes(Diazepam DESITIN®
rectal tubes)
1996First ready-to-useValproateinjection solution(Orfiril® injection solution)
2006First snab-tab Lamotriginefor optimal up-titration(Lamotrigine DESITIN® quadro)
2011First coated mini tabletsof Levetiracetam(Levetiracetam DESITIN®)
2019First Sultiame suspension(Ospolot® Suspension)
1984
First sustained-release Carbamazepine (Timonil® retard)
1998/1999
First sustained-release mini tablets Valproate (Orfiril® long)
2008
First modified-release Oxcarbazepine(Apydan® extent)
2016
First parkinsoncombination therapy in one tablet blister (PramiDopa®)
2019
First Zonisamidesuspension(Zonisol® Suspension)
Driving Growth with Marketing Licences
15.11.2020DYNAMICS OF SUCCESS I Desitin Company Profile11
1993Lamotrigine(Lamictal®)(DE)
1998Beta-Interferon 1a(Rebif®)(DE)
2010Naltrexone(Adepend®)
(DE)
20125-Aminolevulinic acid(Ameluz®)
(DK, NO, SE)
1995
DEC(Almirid®)
(DE)
2001
Paroxetinemesylate(Euplix®) (DE)
Oxcarbazepine(Timox®) (DE)
2007
Naltrexone(Naltrexon HCI aop)
(DE)
2008
Stiripentol(Diacomit®)
(DE, DK, FI, NO, SE,CZ, RO, SK)
2011
Tetrabenazine(Tetmodis®)
(DE)
2016Riluzole liquid(Teglutik®)
(DE)
2017
Apomorphine(Apomorphine Archimedes)
(DE)
2007Piribedil (CLARIUM®) (DE)Botulinum Toxin A (Xeomin®) (DK, NO, CZ, RO, SK)
Total Turnover in millions of EUR (Business Year: Oct 1st to Sept 30th)
Our Performance at a Glance
15.11.2020DYNAMICS OF SUCCESS I Desitin Company Profile12
INTERNATIONAL
GERMANY
0
20
40
60
80
100
120
14007
/08
09/1
0
11/1
2
13/1
4
15/1
6
17/1
8
19/2
0
milli
on €
Our Share of Sales by Regions
15.11.2020DYNAMICS OF SUCCESS I Desitin Company Profile13
Fiscal Year 2019/20Total Turnover: 118.5 million €
GERMANY
NORTHERN EUROPE
WESTERN EUROPE
EASTERN EUROPE
ROW
57%14%
13%12%4%
Our Share of Sales by Therapeutic Areas
15.11.2020DYNAMICS OF SUCCESS I Desitin Company Profile14
Fiscal Year 2019/20Total Turnover: 118.5 million €
65%
25%5%
3%2%
CNS Products: > 90 %
EPILEPSY = 65%
MOVEMENT DISORDERS = 25%
OTHER INDICATIONS = 10%
Our Production Output
15.11.2020DYNAMICS OF SUCCESS I Desitin Company Profile15
1 Billionsemi-finished goods
FINISHED GOODS
IN HOUSE PRODUCTIONS
SUBCONTRACTED
76%
24%
DYNAMICS OF SUCCESS I Desitin Company Profile16
EPILEPSY MOVEMENTDISORDERS
NEPHRO-LOGY UROLOGY DERMA-
TOLOGY
New Therapeutic Entities,Pediatric Drugs, Orphans
OTX Products: RO, CZ + SK
Late Stage Projects (> Ph IIb)
Our Passion for Partnerships in Europe
15.11.2020
Neurology, e. g.: New / Strategic Indications, e. g.:
New Application Forms: DE
- --- --- --
15.11.2020DYNAMICS OF SUCCESS I Desitin Company Profile17
CANDIDATE INDICATION PHASE I/PK PHASE II PHASE III MAA MARKET
DST-119 buccal
DST-071 oral liquid
DST-096oral solid
DST-100 medical device
Epilepsy
Epilepsy
ObstructiveSleep Apnea
Parkinson‘sDisease
DST-112parenteral
Epilepsy
DST-115oral solid
Our Development Pipeline
DST-111liquid
MRSA Eradication
Ongoing
Complete
Ongoing
Ongoing
Ongoing
2022
2027
2020
2021
2023
2022
2028
Ongoing
Epilepsy
DST-120parenteral
Ongoing 2023Epilepsy
DST-123oral solid Ongoing 2023Epilepsy
Complete
Complete Ongoing
OngoingComplete
Policy of open books: complete transparencyin activities and figures Passion for close co-operations High flexibility of a privately held independent
company Fast decision-making procedures Share of knowledge and experience
Our Strong Commitment in Partnering
15.11.2020DYNAMICS OF SUCCESS I Desitin Company Profile18
DYNAMICS OF SUCCESSDesitin Company Profile
